Following a strategic pivot in early 2023, Biodexa is now positioned as a therapeutics company with a focus on oncology and rare/orphan indications. The current pipeline focus is on the legacy Phase I asset, MTX110, currently undergoing clinical studies in aggressive brain cancers such as glioblastoma (Phase Ib trial ongoing) and diffuse intrinsic pontine glioma, a very rare pediatric cancer. Also, the company added a new preclinical programme, MTD217, targeting leptomeningeal disease, a secondary CNS cancer with poor prognosis. Biodexa recently announced the completion of a Phase 1 study of MTX110 in the treatment of children with newly diagnosed diffuse midline gliomas, with full results expected in Q124. To bolster its pipeline further, the company announced the proposed acquisition of Varian Biopharmaceuticals (a US-based biopharma company developing small-molecule atypical protein kinase C iota inhibitors for the treatment of cancer) in May 2023.